Abstract
Like most infections and certain inflammatory diseases, some therapeutic proteins cause a cytokine-mediated suppression of hepatic drug-metabolizing enzymes, which may lead to pharmacokinetic interactions with small molecule drugs. We propose a new in vitro method to evaluate the whole blood-mediated effects of therapeutic proteins on drug-metabolizing enzymes in human hepatocytes co-cultured with Kupffer cells. The traditional method involves treating hepatocyte co-cultures with the therapeutic protein, which detects hepatocyte and macrophage-mediated suppression of cytochrome P450. The new method involves treating whole human blood with a therapeutic protein to stimulate the release of cytokines from peripheral blood mononuclear cells (PBMC), after which plasma is prepared and added to the hepatocyte co-culture to evaluate cytochrome P450 enzyme expression. In this study, human blood was treated for 24 h at 37°C with bacterial lipopolysaccharide (LPS) or ANC28.1, an antibody against human T-cell receptor CD28. Cytokines were measured in plasma by sandwich immunoassay with electrochemiluminescense detection. Treatment of human hepatocyte co-cultures with LPS or with plasma from LPS-treated blood markedly reduced the expression of CYP1A2, CYP2B6 and CYP3A4. However, treatment of hepatocyte co-cultures with ANC28.1 did not suppress CYP expression but treatment with plasma from ANC28.1-treated blood suppressed CYP1A2, CYP2B6 and CYP3A4 activity and mRNA levels. The results demonstrated that applying plasma from human blood treated with a therapeutic protein to hepatocytes co-cultured with Kupffer cells is a suitable method to identify those therapeutic proteins that suppress CYP expression by an indirect mechanism, namely the release of cytokines from PBMC.

This publication has 45 references indexed in Scilit: